Profile data is unavailable for this security.
About the company
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
- Revenue in TWD (TTM)34.63m
- Net income in TWD-1.95bn
- Incorporated2013
- Employees--
- LocationTanvex BioPharma IncFloor 4, Willow House, Cricket Square,P O BOX 2804GRAND CAYMAN KY1-1112Cayman IslandsCYM
- Websitehttp://www.tanvex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unicocell Biomed Co Ltd | -100.00bn | -100.00bn | 4.68bn | -- | -- | 8.28 | -- | -- | -- | -- | -- | 10.15 | -- | -- | -- | -- | -- | -24.25 | -- | -25.60 | -- | 69.89 | -- | -705.40 | 25.16 | -- | 0.1141 | -- | 70.79 | 34.96 | 7.73 | -- | 9.00 | -- |
| Nang Kuang Pharmaceutical Co Ltd | 2.11bn | 159.13m | 5.44bn | 552.00 | 34.24 | 2.44 | 15.94 | 2.59 | 1.57 | 1.57 | 20.83 | 22.08 | 0.5823 | 1.83 | 7.93 | -- | 4.40 | 6.75 | 6.29 | 9.64 | 34.36 | 34.77 | 7.56 | 12.22 | 0.6212 | 23.03 | 0.117 | 82.74 | 10.81 | 6.92 | -43.63 | 14.41 | 19.51 | 10.76 |
| Sinphar Pharmaceutical Co Ltd | 2.97bn | 405.43m | 6.16bn | 984.00 | 15.23 | 1.91 | 9.91 | 2.08 | 2.41 | 2.41 | 17.68 | 19.22 | 0.4824 | 2.25 | 5.70 | -- | 6.35 | -0.0147 | 8.35 | -0.0203 | 37.81 | 37.49 | 13.17 | -0.0344 | 1.52 | 33.73 | 0.3542 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 58.49 |
| Tanvex Biopharma Inc | 34.63m | -1.95bn | 6.40bn | -- | -- | 12.88 | -- | 184.73 | -14.52 | -14.52 | 0.2583 | 3.03 | 0.0121 | 0.1173 | 8.23 | -- | -68.18 | -49.24 | -83.48 | -53.18 | 57.27 | 49.20 | -5,622.48 | -10,835.34 | 0.594 | -133.04 | 0.84 | -- | 174.11 | -- | -30.22 | -- | -8.09 | -- |
| China Chemical & Pharmaceutical Co Ltd | 8.76bn | 327.98m | 6.62bn | 1.40k | 20.19 | 0.8849 | 10.06 | 0.7552 | 1.10 | 1.10 | 29.36 | 25.09 | 0.6814 | 2.21 | 5.55 | -- | 2.57 | 3.69 | 3.55 | 4.96 | 36.61 | 36.56 | 3.77 | 5.50 | 0.8324 | -- | 0.3172 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Pell Bio Med Technology Co Ltd | 18.03m | -398.76m | 7.77bn | -- | -- | 6.26 | -- | 430.77 | -8.62 | -8.62 | 0.3898 | 21.71 | 0.0147 | 10.59 | 2.64 | -- | -32.59 | -- | -35.02 | -- | -144.96 | -- | -2,225.03 | -- | 12.58 | -- | 0.1275 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
Data as of May 29 2024. Currency figures normalised to Tanvex BioPharma Inc's reporting currency: Taiwan Dollar TWD
0.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 09 May 2024 | 122.63k | 0.08% |
| The Vanguard Group, Inc.as of 31 Jan 2023 | 4.08k | 0.00% |
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
